Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

Phase 3

Completed

• Conditions: Depression

• Registration Number: NCT00225524
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Phase III long-term safety study of Effexor XR in patients with major depression.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-20
• Study First Posted: 2005-09-23
• Status Verified: 2007-05
• Last Update Submitted: 2007-05-22
• Last Update Posted: 2007-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)

Exclusion Criteria

• Patients with schizophrenia or any other psychotic disorder
• Patients with history or presence of bipolar disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events

Secondary Outcome Measures

Name	Time	Method
Quantitative data for laboratory data